ライフサイエンスコーパス: severe combined

1 The recessive mutant scat (severe combined anemia and thrombocytopenia) alternates

2 ssays, flow cytometry, and nonobese diabetic/severe combined immune deficienct mouse transplantation.

3 erapy (GT) for adenosine deaminase-deficient severe combined immune deficiency (ADA-SCID) can provide

4 lting in primary immune deficiencies such as severe combined immune deficiency (SCID) and X-linked ag

5 njected human CD34(+) cells in the hearts of severe combined immune deficiency (SCID) mice after expe

6 with diverse clinical phenotypes, including severe combined immune deficiency (SCID), autoimmunity,

7 immune deficiency diseases (PIDs), including severe combined immune deficiency (SCID), Wiskott-Aldric

8 a and result in the clinical presentation of severe combined immune deficiency (SCID).

9 splantation (HSCT) for infants with X-linked severe combined immune deficiency (SCID-X1) lacking a ma

10 liver urokinase-type plasminogen activator, severe combined immune deficiency (uPA-SCID) mice" (chim

11 For many years, severe combined immune deficiency diseases, which are ch

12 une cell reconstitution in nonobese diabetic severe combined immune deficiency gamma-/- mice reconsti

13 otoxic mechanisms in mice homozygous for the severe combined immune deficiency mutation in the protei

14 in upper airway samples from an infant with severe combined immune deficiency syndrome and persisten

15 mary immunodeficiency, ranging from T(-)B(-) severe combined immune deficiency to delayed-onset disea

16 was also activated in patients with X-linked Severe Combined Immune Deficiency treated with gene ther

17 ities in thrombus formation in patients with severe combined immune deficiency, Glanzmann's thrombast

18 atments for several PIDs, including forms of severe combined immune deficiency, Wiskott-Aldrich syndr

19 erved in the metastatic lung cancer model in Severe Combined Immune Deficiency-beige (SCID-bg) mice,

20 mol of Tyr(4)-BBN: in vivo GRPR blockade) in severe combined immune deficient mice bearing PC-3 xenog

21 In vivo studies conducted in male severe combined immune deficient mice bearing PSMA-posit

22 rus type 1 infection were tested in nonobese severe combined immune-deficient mice reconstituted with

23 In severe combined immune-deficient mice, overexpression of

24 that overexpress miR-26a or its inhibitor in severe combined immune-deficient mice.

25 ted into peri-infarct areas of the hearts of severe combined immune-deficient mice.

26 burnetii infection-induced diseases in both severe combined immunity-deficient (SCID) and muMT mice

27 A subgroup of severe combined immunodeficiencies (SCID) is characteriz

28 ells injected intraperitoneally (ie, in CB17 severe combined immunodeficiencies) and significantly in

29 established tumors (ie, in nonobese diabetic-severe combined immunodeficiencies) that were derived fr

30 affected with adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) and set out

31 c contrast, 39 adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) patients hav

32 'difficult' conditions [adenosine deaminase-severe combined immunodeficiency (ADA-SCID), major histo

33 ites that destroy the immune system, causing severe combined immunodeficiency (ADA-SCID), often refer

34 HTLV-1-infected humanized nonobese diabetic severe combined immunodeficiency (HU-NOD/SCID) mice were

35 oss of T cells in a spectrum including leaky severe combined immunodeficiency (LS) and Omenn syndrome

36 under the renal capsule of nonobese diabetic severe combined immunodeficiency (NOD SCID) mice with MS

37 l CD34(+) progenitors into nonobese diabetic/severe combined immunodeficiency (NOD-SCID) mice resulte

38 A-overexpressing tumors in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with pa

39 (STZ)-induced diabetes in nonobese diabetic severe combined immunodeficiency (NOD/SCID) mice.

40 telangiectasia and a class of Radiosensitive-Severe Combined Immunodeficiency (RS-SCID), respectively

41 function therefore results in radiosensitive severe combined immunodeficiency (RS-SCID).

42 function of adenosine deaminase (ADA) cause severe combined immunodeficiency (SCID) and affect many

43 with ARTEMIS deficiency usually present with severe combined immunodeficiency (SCID) and cellular rad

44 oietic-cell transplantation in children with severe combined immunodeficiency (SCID) and other primar

45 Population-based newborn screening for severe combined immunodeficiency (SCID) and related diso

46 Severe combined immunodeficiency (SCID) and X-linked aga

47 Severe combined immunodeficiency (SCID) arises from diff

48 Severe combined immunodeficiency (SCID) can be cured by

49 Severe combined immunodeficiency (SCID) carries a poor p

50 tivating gene 1 (RAG1) deficiency results in severe combined immunodeficiency (SCID) caused by a comp

51 Severe combined immunodeficiency (SCID) comprises a grou

52 Severe combined immunodeficiency (SCID) comprises a hete

53 to the pathology of Omenn syndrome and leaky severe combined immunodeficiency (SCID) has not been pre

54 The inclusion of severe combined immunodeficiency (SCID) in a Europe-wide

55 in reticular dysgenesis (RD), a rare form of severe combined immunodeficiency (SCID) in humans.

56 Severe combined immunodeficiency (SCID) is a life-threat

57 Early recognition of severe combined immunodeficiency (SCID) is a pediatric e

58 Adenosine deaminase (ADA)-severe combined immunodeficiency (SCID) is caused by gen

59 Severe combined immunodeficiency (SCID) is characterized

60 Severe combined immunodeficiency (SCID) is characterized

61 verexpressing SDF-1alpha were xenografted on severe combined immunodeficiency (SCID) mice.

62 th in soft agar and enhanced tumor growth in severe combined immunodeficiency (SCID) mice.

63 tiated by transfer of their splenocytes into severe combined immunodeficiency (SCID) mice.

64 ed autophagy in human skin xenografts in the severe combined immunodeficiency (SCID) mouse model of V

65 me for at least a month in both nude rat and severe combined immunodeficiency (SCID) mouse xenograft

66 se of nonobese diabetic (NOD) mice, NOD with severe combined immunodeficiency (scid) mutation (SCID)

67 fetal liver cells in nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) or NOD/SCID/gamm

68 ic and nonimmunologic outcomes in cohorts of severe combined immunodeficiency (SCID) patients with ei

69 Severe combined immunodeficiency (SCID) represents conge

70 onsortium (PIDTC) is enrolling children with severe combined immunodeficiency (SCID) to a prospective

71 Newborn screening for severe combined immunodeficiency (SCID) using assays to

72 Severe combined immunodeficiency (SCID) with a complete

73 ations that impair Rag2 function can lead to severe combined immunodeficiency (SCID), a condition cha

74 the 91 position found in some patients with severe combined immunodeficiency (SCID), and the double

75 d T-cell reconstitution in many infants with severe combined immunodeficiency (SCID), but correction

76 have been identified, often associated with severe combined immunodeficiency (SCID), consistent with

77 used into young horses (foals) affected with severe combined immunodeficiency (SCID), followed by cha

78 of typical profound T-cell dysfunction (TD), severe combined immunodeficiency (SCID), has been carefu

79 the cervical spinal cords of adult mice with severe combined immunodeficiency (SCID), human pluripote

80 cell transplantation (HCT) for patients with severe combined immunodeficiency (SCID), including survi

81 hly relevant per se because in patients with severe combined immunodeficiency (SCID), infections caus

82 minase (ADA) deficiency, a cause of X-linked severe combined immunodeficiency (SCID), is a case in po

83 t profound primary immunodeficiency disease, severe combined immunodeficiency (SCID), is fatal in inf

84 The most severe form, severe combined immunodeficiency (SCID), presents with p

85 the natural history of patients treated for severe combined immunodeficiency (SCID), Wiskott-Aldrich

86 abrogate lymphocyte development and lead to severe combined immunodeficiency (SCID), XLF mutations c

87 tations in ORAI1 or STIM1 genes present with severe combined immunodeficiency (SCID)-like disease.

88 ion (DRG) xenografts maintained in mice with severe combined immunodeficiency (SCID).

89 population-based newborn screening (NBS) for severe combined immunodeficiency (SCID).

90 cell transplantation (HSCT) in patients with severe combined immunodeficiency (SCID).

91 in a significant proportion of patients with severe combined immunodeficiency (SCID).

92 (HCT) of adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

93 recombination, hence loss of DNA-PK leads to severe combined immunodeficiency (SCID).

94 erleukin-2 gamma-chain receptor (IL2RG)/JAK3 severe combined immunodeficiency (SCID).

95 g immune plasma in young horses (foals) with severe combined immunodeficiency (SCID).

96 systemic metabolic disease characterized by severe combined immunodeficiency (SCID).

97 scribe the generation of a marmoset model of severe combined immunodeficiency (SCID).

98 e T- or B-lymphocytes and are diagnosed with severe combined immunodeficiency (SCID).

99 ls (1 Arabian and 1 Arabian-pony cross) with severe combined immunodeficiency (SCID).

100 T-cell development, clinically presenting as severe combined immunodeficiency (SCID).

101 repair pathway result in radiation-sensitive severe combined immunodeficiency (SCID).

102 cured immunodeficiencies including X-linked severe combined immunodeficiency (SCID-X1) and adenine d

103 X-linked severe combined immunodeficiency (SCID-X1) caused by mut

104 X-linked Severe Combined Immunodeficiency (SCID-X1) is a genetic

105 ical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney mu

106 fective vectors for gene therapy of X-linked severe combined immunodeficiency (SCID-X1), we have eval

107 m healthy donors and a subject with X-linked severe combined immunodeficiency (SCID-X1).

108 vector for the correction of canine X-linked severe combined immunodeficiency (SCID-X1).

109 growth in vivo in hairless outbred mice with severe combined immunodeficiency (SHO-Prkdc(scid)Hr(hr))

110 X-linked severe combined immunodeficiency (X-SCID) is an immune d

111 clinical case of an RSV-infected infant with severe combined immunodeficiency and effectively no adap

112 g its goal of defining the true incidence of severe combined immunodeficiency and providing early tre

113 Omenn syndrome (OS) is a rare severe combined immunodeficiency associated with autoimm

114 g in California established the incidence of severe combined immunodeficiency at 1 in 66,250 live bir

115 raftment is a common finding in infants with severe combined immunodeficiency but is not typically ob

116 correct T-cell deficiencies in patients with severe combined immunodeficiency by replacing resident t

117 delivered via osmotic pump in an intratibial severe combined immunodeficiency CAG myeloma model or in

118 eficiency CAG myeloma model or in a systemic severe combined immunodeficiency CAG-heparanase model of

119 Severe combined immunodeficiency can be caused by loss-o

120 ells has emerged as a convincing therapy for severe combined immunodeficiency caused by ILR2G mutatio

121 chain cytokine receptor subunit give rise to severe combined immunodeficiency characterized by lack o

122 Norovirus incidence was compared between severe combined immunodeficiency children with (n = 10)

123 Further, the nonobese diabetic severe combined immunodeficiency common gamma chain knoc

124 Newborn screening for severe combined immunodeficiency detects athymic patient

125 The approach to the diagnosis of severe combined immunodeficiency disease (SCID) and rela

126 wn to lead to an autosomal recessive form of severe combined immunodeficiency disease (SCID).

127 PET experiments were performed in severe combined immunodeficiency disease mice inoculated

128 Patients with severe combined immunodeficiency disease who have matche

129 ications of anti-CD3epsilon mAb treatment in severe combined immunodeficiency forms characterized by

130 r from healthy donors were injected into NOD-severe combined immunodeficiency gammac(-/-) mice, follo

131 and patients with atypical presentations of severe combined immunodeficiency gene mutations presents

132 patients with adenosine deaminase deficient severe combined immunodeficiency have identified neutrop

133 homing, and engraftment in nonobese diabetic/severe combined immunodeficiency IL-2gamma(null) (NSG) m

134 ndent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05).

135 lial cells, leading to increased survival of severe combined immunodeficiency mice after transplantat

136 n vivo after subcutaneous transplantation in severe combined immunodeficiency mice and differentiated

137 umab and copper-DOTA-conatumumab was done in severe combined immunodeficiency mice bearing Colo205 xe

138 In female CB17 severe combined immunodeficiency mice bearing Colo205 xe

139 ession by PET and ex vivo biodistribution in severe combined immunodeficiency mice bearing H2009 tumo

140 in vivo experiments, 6- to 12-wk-old female severe combined immunodeficiency mice bearing M21 xenogr

141 ol Tyr(4)-BBN: for in vivo GRPR blockade) in severe combined immunodeficiency mice bearing PC-3 xenog

142 LL cells transplanted onto nonobese diabetic/severe combined immunodeficiency mice faithfully recapit

143 Finally, YT cells transplanted into severe combined immunodeficiency mice had an invasive be

144 Six nonobese diabetic severe combined immunodeficiency mice received transplan

145 tumor transplantation in Non-obese diabetic/severe combined immunodeficiency mice that the HAGE knoc

146 ansplanted nonobese diabetic background with severe combined immunodeficiency mice to assess suppress

147 Nonobese diabetic/severe combined immunodeficiency mice transplanted with

148 The tumorigenicity of cells in severe combined immunodeficiency mice was augmented to a

149 Humanized urokinase plasminogen activator/severe combined immunodeficiency mice were used to estab

150 transplanted with MSCs in nonobese diabetic severe combined immunodeficiency mice with a significant

151 nd decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with P

152 EB-silenced MM cells were then injected into severe combined immunodeficiency mice, and tumor growth

153 In a xenograft analysis of severe combined immunodeficiency mice, cisplatin also ef

154 MSCs was not observed in non-obese diabetic/severe combined immunodeficiency mice, indicating the im

155 In a tumor xenograft model in severe combined immunodeficiency mice, inoculation of hu

156 esis in immunocompromised non-obese diabetic/severe combined immunodeficiency mice, supporting an onc

157 ppresses the tumorigenicity of A549 cells in severe combined immunodeficiency mice.

158 ro, and suppressed tumor xenograft growth in severe combined immunodeficiency mice.

159 antly inhibited cholangiocarcinoma growth in severe combined immunodeficiency mice.

160 in vitro and in engrafted nonobese diabetic-severe combined immunodeficiency mice.

161 ted in the choroids of six nude rats and six severe combined immunodeficiency mice.

162 otype when transplanted to nonobese diabetic/severe combined immunodeficiency mice.

163 tive transfer, delayed diabetes onset in NOD.severe combined immunodeficiency mice.

164 presses the tumorigenicity of MCF-7 cells in severe combined immunodeficiency mice.

165 in human PBMC cultures and in PBMC-engrafted severe combined immunodeficiency mice.

166 d into the skeletal muscle of dystrophic mdx/severe combined immunodeficiency mice.

167 g soft agar assays and xenograft analysis of severe combined immunodeficiency mice.

168 ive, PD-L1-negative, and mixed tumor-bearing severe combined immunodeficiency mice.

169 lanted subcutaneously into nonobese diabetic severe combined immunodeficiency mice.

170 he same day prior to graft implantation into severe combined immunodeficiency mice.

171 ing CD-1 nu/nu and LNCaP tumor-bearing CB-17 severe combined immunodeficiency mice.

172 In human artery-severe combined immunodeficiency mouse chimeras, in whic

173 nd virulence in human skin xenografts in the severe combined immunodeficiency mouse model in vivo.

174 tensively in infected skin xenografts in the severe combined immunodeficiency mouse model of VZV path

175 Using a nonobese diabetic/severe combined immunodeficiency mouse model, those anti

176 tem with experimental systemic infections of severe combined immunodeficiency Mus musculus with the b

177 tuted with a synthetic LAT gene bearing this severe combined immunodeficiency mutation.

178 ency causes T(-)B(+) natural killer-positive severe combined immunodeficiency or T-cell lymphopenia w

179 h overexpression of Bcl2 does not rescue the severe combined immunodeficiency phenotype in Ku70-defic

180 We describe a pedigree affected by a severe combined immunodeficiency phenotype with absent T

181 A 14-year-old boy with severe combined immunodeficiency presented three times t

182 - and B-lymphocyte-independent protection of severe combined immunodeficiency SCID mice from dissemin

183 ell lymphopenia, patients with ADA-deficient severe combined immunodeficiency showed a partial block

184 ations that inactivate Artemis cause a human severe combined immunodeficiency syndrome associated wit

185 chronic inflammation, muscle weakness, and a severe combined immunodeficiency syndrome.

186 We performed a multicenter survey of severe combined immunodeficiency transplantation centers

187 nts with adenosine deaminase (ADA)-deficient severe combined immunodeficiency using 2 slightly differ

188 SCID (severe combined immunodeficiency) mice underwent left an

189 When xenografted into SCID (severe combined immunodeficiency) mice, the expression o

190 s been found in NOD/SCID (non-obese diabetic/severe combined immunodeficiency) mice.

191 d engraftment in NOD-SCID (nonobese diabetic-severe combined immunodeficiency) mouse myocardium incre

192 ype per heart) was tested in infarcted SCID (severe combined immunodeficiency)-Beige mice.

193 kidney capsules of SCID mice (ie, mice with severe combined immunodeficiency).

194 ions in Janus kinase 3 (JAK3) are a cause of severe combined immunodeficiency, but hypomorphic JAK3 d

195 ete recovery occurred in VLP-dosed mice with severe combined immunodeficiency, but not in wild-type m

196 orrection of disease phenotypes for X-linked severe combined immunodeficiency, chronic granulomatous

197 d adults with specific forms of PID, such as severe combined immunodeficiency, for over 10 years.

198 treatment advances and newborn screening for severe combined immunodeficiency, has resulted in improv

199 gene replacement for Hemophilia B, X-linked Severe Combined Immunodeficiency, Leber's Congenital Ama

200 ere divided into 3 main categories: T(-)B(-) severe combined immunodeficiency, Omenn syndrome, and co

201 mmune system since it did not occur in nude, severe combined immunodeficiency, or T-cell depleted mic

202 is with neutrophil infiltration in mice with severe combined immunodeficiency, which is accompanied b

203 ) were given intranasally or i.p. to newborn severe combined immunodeficiency-beige mice exposed to 9

204 yptosporidium parasites from 6 of 7 infected severe combined immunodeficiency-beige mice, and the par

205 Nonobese diabetic-severe combined immunodeficiency-gammac(-/-) mice were i

206 th and prevented bone destruction in vivo in severe combined immunodeficiency-hu mice.

207 rchy contains a rare CD34(-) population with severe combined immunodeficiency-repopulating capacity.

208 ally attenuated MM tumor growth in mice with severe combined immunodeficiency.

209 benefits with gene therapy for ADA-deficient severe combined immunodeficiency.

210 ng Tgfb1-null mutant mice on a background of severe combined immunodeficiency.

211 in Matrigel, and formed tumors in mice with severe combined immunodeficiency.

212 ratoma assays in nonobese diabetic mice with severe combined immunodeficiency.

213 c), which is mutated in humans with X-linked severe combined immunodeficiency.

214 ion and subsequently received a diagnosis of severe combined immunodeficiency.

215 in humans and null mutations in mice lead to severe combined immunodeficiency.

216 ly, such protection occurred without causing severe combined immunodeficiency.

217 y CLL cells proliferate in nonobese diabetes/severe combined immunodeficiency/gammac(null) mice under

218 geneic hosts as well as in nonobese diabetic/severe combined immunodeficiency/interleukin 2Rgamma(nul

219 nstitute immune-deficient (nonobese diabetic/severe combined immunodeficiency/interleukin-2 gammac re

220 Therefore, we created a nonobese diabetic/severe combined immunodeficiency/interleukin-2 receptor-

221 stitution by transplanting nonobese diabetic/severe combined immunodeficiency/interleukin-2 receptor-

222 X-linked severe-combined immunodeficiency (SCID-X1) has been trea

223 Human fetal lung tissue was implanted into severe combined immunodeficient (CB17-scid) mice and ino

224 marrow of immunodeficient nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice.

225 higher tumor incidence in nonobese diabetic/severe combined immunodeficient (NOD/SCID) Ilgamma2(null

226 n the peritoneal cavity of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.

227 We examined whether the nonobese diabetic/severe combined immunodeficient (NOD/scid) mouse, which

228 A nonobese diabetic/severe combined immunodeficient (NOD/SCID) murine xenogr

229 (+) B-cell malignancies in nonobese diabetic/severe combined immunodeficient (NOD/SCID)/gamma(c)(null

230 regression was blocked in nonobese diabetic/severe combined immunodeficient (NOD/SCID-gamma) mice, w

231 titumor effects of MEDI-575 in tumor-bearing severe combined immunodeficient (SCID) mice and in genet

232 in the brain's extracellular space of C.B.17 severe combined immunodeficient (scid) mice and tumor ce

233 Severe combined immunodeficient (SCID) mice carry a germ

234 iver homogenates after 24 serial passages in severe combined immunodeficient (SCID) mice caused sever

235 and their splenocytes were transferred into severe combined immunodeficient (SCID) mice to induce IT

236 Severe combined immunodeficient (SCID) mice were infecte

237 WT) mice were subjected to DNFB-induced CHS, severe combined immunodeficient (SCID) mice were injecte

238 When implanted subcutaneously in severe combined immunodeficient (SCID) mice, MDA-PCa-118

239 AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting

240 or after coinjection of PA in tumor-bearing severe combined immunodeficient (SCID) mice.

241 ll as metastatic tumor growth in the lung of severe combined immunodeficient (SCID) mice.

242 and their splenocytes were transferred into severe combined immunodeficient (SCID) mice.

243 and tumor formation in an immunocompromized severe combined immunodeficient (SCID) mouse model of or

244 RAG1-mutants from severe combined immunodeficient (SCID) patient cells sho

245 th pleiotrophin also substantially increased severe combined immunodeficient (SCID)-repopulating cell

246 wn in the epithelium-free mammary fat pad of severe combined immunodeficient (SCID)/Beige and nonobes

247 and after transplantation into the livers of severe combined immunodeficient (SCID)/beige mice.

248 g plasmablasts can be enriched in vivo, in a severe combined immunodeficient (SCID)/beige mouse host.

249 (+) PMF CD34(+) cells into nonobese diabetic/severe combined immunodeficient (SCID)/IL-2Rgamma(null)

250 Humanized nonobese diabetic severe combined immunodeficient common gamma chain-defic

251 s to restore euglycemia in nonobese diabetic/severe combined immunodeficient diabetic recipients was

252 Nonobese diabetic severe combined immunodeficient gammac(-/-) (NSG) mice r

253 In contrast to nonobese diabetic severe combined immunodeficient Il2rg(-/-) (NSG) mice, h

254 uction of the human HGF ligand in transgenic severe combined immunodeficient mice (hHGF(tg)-SCID mice

255 In severe combined immunodeficient mice bearing SKOV3 tumor

256 PET/CT small-animal imaging was performed in severe combined immunodeficient mice bearing solid and d

257 An in vivo efficacy trial with severe combined immunodeficient mice implanted with subc

258 5(+) T cells to infected macrophage-depleted severe combined immunodeficient mice induced CNS demyeli

259 Nonobese diabetic severe combined immunodeficient mice lacking the cytokin

260 t VEGF111 addition before transplantation to severe combined immunodeficient mice ovaries.

261 racranial implantation of human gliomas into severe combined immunodeficient mice showed a marked red

262 Female severe combined immunodeficient mice were fed a low-fat/

263 Severe combined immunodeficient mice were given injectio

264 M21 (human melanoma)-bearing severe combined immunodeficient mice were used for biodi

265 inst subcutaneous B-cell tumor xenografts in severe combined immunodeficient mice with comparable or

266 HCV-infected urokinase plasminogen activator-severe combined immunodeficient mice with livers repopul

267 Severe combined immunodeficient mice xenografted with M2

268 volume, rate of metastasis, and mortality of severe combined immunodeficient mice xenografted with PC

269 neither resulted in weight loss nor death in severe combined immunodeficient mice, and pock lesions w

270 In severe combined immunodeficient mice, the antitumor effi

271 lls, bone marrow chimeras, and reconstituted severe combined immunodeficient mice, we identify the pr

272 ation of SKOV3ip1 cells in nonobese diabetic/severe combined immunodeficient mice, with increased pho

273 -reperfusion-injured adult nonobese diabetic-severe combined immunodeficient mice.

274 n into the left subrenal capsule of diabetic severe combined immunodeficient mice.

275 ression was studied in nonobese diabetic and severe combined immunodeficient mice.

276 we implanted human-derived glioma cells into severe combined immunodeficient mice.

277 ling of human coronary artery transplants in severe combined immunodeficient mice.

278 nd also in tumors in prostate-tumor-bearing, severe combined immunodeficient mice.

279 or supplemented (GFS) matrigel into diabetic severe combined immunodeficient mice.

280 sicles in a model of glycerol-induced AKI in severe combined immunodeficient mice.

281 asion assays, and/or injected into flanks of severe combined immunodeficient mice; xenograft tumor gr

282 Finally, using a humanized severe combined immunodeficient mouse model of lymphocyt

283 cells, using a xenogeneic nonobese diabetic/severe combined immunodeficient mouse model.

284 inant hepatic failure in a nonobese diabetic severe combined immunodeficient mouse model.

285 eutic treatments using both cell culture and severe combined immunodeficient mouse models.

286 6Mre11(ATLD1/ATLD1) and C57BL/6(Prkdc/SCID) (severe combined immunodeficient) mice exposed to low-dos

287 edium before transfer to Prkdc(scid)-mutant (severe combined immunodeficient) mice.

288 an CD19(+) tumors in immunocompromised SCID (severe combined immunodeficient)-Beige mice.

289 (PMNs) and in human intestinal xenografts in severe-combined immunodeficient (SCID-HU-INT) mice, a no

290 owth of malignant mesothelioma xenografts in severe-combined immunodeficient mice and extended host s

291 cells were injected intratibially in C3H and severe-combined immunodeficient mice.

292 C1 was seen toward H460 tumor xenografts in severe-combined immunodeficient mice.

293 um antibodies to the systemic compartment of severe-combined-immunodeficient (SCID) mice temporarily

294 line (EGI-1) after xenotransplantation into severe-combined-immunodeficient mice, (3) expression of

295 ilator dependent and, where tested, revealed severe combined mitochondrial respiratory chain deficien

296 outcome (preterm delivery, NICU, SGA); and "severe" combined outcome (early preterm delivery, NICU,

297 eral" combined outcome, 34.1% versus 90.0%; "severe" combined outcome, 21.4% versus 80.0%; P<0.001).

298 nation (p.Val255Ile and p.Arg282Pro) and the severe combined phenotype (p.Asn414Lys) resulted in norm

299 for H-ABC (p.Asp249Asn), DYT4 (p.Arg2Gly), a severe combined phenotype with hypomyelination and encep

300 xidase deficiency in all patients tested and severe, combined respiratory chain complex activity defi